Challenges of Treating Gynecological Cancers in the Greater Phoenix Area

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 blockade, or the use of fam-trastuzumab deruxtecan-nxki in endometrial cancer.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Datopotamab deruxtecan elicited encouraging antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

While the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial missed its end point of disease-free survival, benefits were still observed in the dMMR subgroup.